Molecular Partners AG provided earnings guidance for the year 2022. Based upon the 2022 year to date received payments from Novartis, the Group currently anticipates reporting an operating profit as well as positive cash flows from operations for the year ended December 31, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.745 CHF | -0.13% | +10.15% | +8.87% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.87% | 139M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- MOLN Stock
- News Molecular Partners AG
- Molecular Partners AG Provides Earnings Guidance for the Year 2022